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Available online 18 October 2014In the current issue of the journal, Abdelbaky et al. [1] present a
very interesting study addressing the association of aortic valve
inﬂammation and calciﬁcation. To ascertain whether aortic valve
inﬂammation precedes subsequent valvular calciﬁcation they uti-
lized sequential PET/CT scans performed for cancer surveillance in
patients with stable oncological disorders. Computed tomography
provided information regarding the presence and extent of calci-
ﬁcation (structural information), while PET provided functional/
activity information. 18Fluoro -deoxyglucose (FDG) is used exten-
sively in oncological PET imaging and has been shown to be
selectively taken up by inﬂammatory cells, accumulating in nascent
atherosclerotic plaques and the aortic valve [2,3]. In the current
study Abdelbaky et al. [1] showed that FDG uptake in the aortic
valve was higher among patients who showed subsequent pro-
gression of calciﬁcation, especially in patients with no detectable
calciﬁcation at baseline. Several traditional risk factors for athero-
sclerosis were associatedwith inﬂammation and calciﬁcation of the
aortic valve at the time of the ﬁrst scan including age, diabetes
mellitus, dyslipidemia and hypertension. However, on multivari-
able analyses only age and a quantitative measure of FDG uptake
(maximum standardized uptake value (SUVmax)) were associated
with inception or progression of valve calciﬁcation [1]. In a prior
publication the same authors made a very similar observation in
aortas, where inﬂammation preceded subsequent calciﬁcation [4].
Is inﬂammation therefore a condition sine-qua-non for future
calciﬁcation of the aortic valve? Certainly there were patients who
demonstrated tracer uptake at baselinewho did not calcify during a
median follow up of 2 years, hence it does not appear that
inﬂammation is a necessary and sufﬁcient condition for future
calciﬁcation. Nonetheless, numerous pieces of evidence point to theDOI of original article: http://dx.doi.org/10.1016/j.atherosclerosis.2014.11.026.
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of the aortic valve.
Atherosclerosis and aortic valve calciﬁcation share the same risk
factors [5] and these may induce inﬂammation. However, in the
current study inﬂammationwas associatedwith future calciﬁcation
independent of all risk factors except for age [1]; hence one won-
ders if risk factors and inﬂammation are at all correlated in aortic
valve disease. Of interest, inﬂammation showed a close association
with future valvular calciﬁcation but not pre-existing calciﬁcation
[1]. This could suggest that long standing calciﬁcation becomes
inert and/or that new stimuli may ignite a strong inﬂammatory
response. Is it possible that calciﬁcation itself may promote
inﬂammation, so is inﬂammation the chicken or the hen? Although
limited, there is some experimental and human evidence that this
might be the case. Calciﬁcation of the aortic valve is associated with
disruption of the basal membrane, inﬁltration of inﬂammatory cells
and lipids deposition [6,7]. Nadra et al. [8] showed that human
macrophages exposed in culture to calcium-phosphate crystals
internalize the crystals in vacuoles and release inﬂammatory cy-
tokines (TNF-a, IL-1b and IL-8) via a protein-kinase-C dependent
pathway. TNF-a is capable of inducing osteoblastic differentiation
of vascular smooth muscle cells therefore initiating calciﬁcation of
the interstitium [9]. Furthermore, recent evidence suggests that
macrophages are capable of releasing matrix vesicles that are rich
in annexin V and alkaline phosphatase, with high calcifying po-
tential [10]. These results suggest that calcium may promote
inﬂammation which in turn will enhance further calciﬁcation. In a
randomized trial of patients affected by end-stage renal disease the
compound Sevelamer arrested the progression of valvular calciﬁ-
cation, while calcium-based phosphate binders allowed further
progression [11]. Sevelamer is a non-absorbable polymer used as a
gut phosphate binder and has lipid-lowering as well as mild anti-
inﬂammatory activities [12]. This trial provided partial support to
the hypothesis that calcium and inﬂammation may be part of a
“vicious cycle”.
What other risk factors could potentially ignite inﬂammation
and calciﬁcation of the aortic valve? As oxidized lipids are found in
calcifying aortic valves, it has been suggested that they could pro-
mote osteoblastic differentiation of valvular ﬁbroblasts and mac-
rophages via activation of the LDL receptor protein-5 (LRP5)/Wnt
and Runx2/Cbfa-1 pathways, eventually inducing calciﬁcation [13].
Unfortunately, several trials of statin therapy to reduce serum LDLr the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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ﬁcation [14,15]. These trials may have been initiated too late in the
process of calciﬁcation to slow it or reverse it, however there is also
laboratory evidence that statins may promote valvular calciﬁcation
rather than inhibit it [16]. Interestingly, in patients with the genetic
disorder familial hypercholesterolemia LDL apheresis slows
atherosclerosis progression but aortic valve calciﬁcation continues
to advance [17e19]. This suggests that other factors, likely related
to LDL-receptor deﬁciency or abnormal function, play a role which
is unlikely to be mediated by inﬂammation [20]. It remains to be
seenwhether the new PCSK-9 inhibitors that have little to no effect
on inﬂammation while reducing LDL levels dramatically and the
level of Lp(a) by 20e25% [21], will impact aortic valve calciﬁcation
in familial hypercholesterolemia.
Evidently much remains to be done to attain a better under-
standing of the mechanisms and potential therapeutic approaches
to aortic valve calciﬁcation. In the meantime the study by Abdel-
baky et al. [1] adds another thread to the thickly woven mystery of
the most common human valvular disease.References
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